News
KRSA
24.54
-6.34%
-1.66
*News On Cyclerion Therapeutics Inc. (CYCN) Now Under KRSA
Dow Jones · 22h ago
Cyclerion Therapeutics trading halted, news pending
TipRanks · 1d ago
Weekly Report: what happened at CYCN last week (0831-0904)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 6d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 6d ago
Weekly Report: what happened at CYCN last week (0824-0828)?
Weekly Report · 08/31 09:02
Cyclerion Shareholders Approve Key Measures for Korsana Merger
TipRanks · 08/27 10:27
Cyclerion Therapeutics Details Merger-Related Risks and Uncertainties
TipRanks · 08/25 20:51
Weekly Report: what happened at CYCN last week (0817-0821)?
Weekly Report · 08/24 09:02
Weekly Report: what happened at CYCN last week (0810-0814)?
Weekly Report · 08/17 09:02
Weekly Report: what happened at CYCN last week (0803-0807)?
Weekly Report · 08/10 09:02
Weekly Report: what happened at CYCN last week (0727-0731)?
Weekly Report · 08/03 09:02
Weekly Report: what happened at CYCN last week (0720-0724)?
Weekly Report · 07/27 09:02
Weekly Report: what happened at CYCN last week (0713-0717)?
Weekly Report · 07/20 09:02
Weekly Report: what happened at CYCN last week (0706-0710)?
Weekly Report · 07/13 09:02
Weekly Report: what happened at CYCN last week (0629-0703)?
Weekly Report · 07/06 09:02
Weekly Report: what happened at CYCN last week (0622-0626)?
Weekly Report · 06/29 09:02
Weekly Report: what happened at CYCN last week (0615-0619)?
Weekly Report · 06/22 09:02
Weekly Report: what happened at CYCN last week (0608-0612)?
Weekly Report · 06/15 09:02
Weekly Report: what happened at CYCN last week (0601-0605)?
Weekly Report · 06/08 09:02
More
Webull provides a variety of real-time KRSA stock news. You can receive the latest news about Korsana Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About KRSA
Korsana Biosciences, Inc., formerly Cyclerion Therapeutics, Inc., is a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. The Company's lead program, KRSA-028, is a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, it is advancing a pipeline of innovative therapies for neurodegenerative diseases.